Charts

05 Feb, 2023

News

01 Feb, 2023
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today issued the following letter to its stockholders: To our Valued Stockholders: I am excited to update you on our significant accomplishments for 2022 and to review our priorities for the
24 Jan, 2023
CARLSBAD, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the initiation of Good Laboratory Practice (GLP) toxicology studies of its lead oncology program, QN-302, a G4-selective transcription inhibitor currently in development for
23 Jan, 2023
Qualigen Therapeutics, Inc. Benedict M. Abugan CARLSBAD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the promotion of Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications. Mr. Abugan has over tw
10 Jan, 2023
Gainers Hepion Pharmaceuticals (NASDAQ:HEPA) stock increased by 72.2% to $0.79 during Tuesday's after-market session. At the close, ...
CARLSBAD, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead drug candidate, QN-302, for the indication of Pancreatic Cancer. QN-302
05 Jan, 2023
CARLSBAD, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today shares an update on its majority-owned subsidiary, NanoSynex Ltd. (“NanoSynex”), the progress made during 2022, and objectives for 2023 concerning the commercialization plans for its i
12 Dec, 2022
CARLSBAD, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that it has received written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance
07 Dec, 2022
CARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that it has received feedback from the FDA following a pre-Investigational New Drug (pre-IND) interaction regarding the development pathway to a Phase 1 clinical trial of QN-
01 Dec, 2022
By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update Preclinical Data on QN-302 Presented at AACR Conference on Pancreatic Cancer In September 2022, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced the presentation of two posters on QN-302 at the AACR 8 th Special Conference on Pancreatic Cancer. The data presented include information on the compound’s safety,
30 Nov, 2022
During Wednesday's session, 107 stocks hit new 52-week lows. Key Facts About Today's 52-Week ...
22 Nov, 2022
Action to comply with continued listing requirements for Nasdaq Capital Market CARLSBAD, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics, Inc.), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that its board of directors (the “Board”) has approved a 1-for-10 reverse stock split of the Com
18 Nov, 2022
Gainers LumiraDx (NASDAQ:LMDX) stock moved upwards by 22.4% to $1.42 during Friday's after-market session. At the close, LumiraDx's ...
17 Nov, 2022
Qualigen Therapeutics ( NASDAQ:QLGN ) Third Quarter 2022 Results Key Financial Results Revenue: US$1.44m (up 25% from...
15 Nov, 2022
Q3 2022 FastPack ® sales increased approximately 25% year-over-yearCompany continues to execute on and advance core therapeutic programs CARLSBAD, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics, Inc.), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces its financial results for the third qu
10 Nov, 2022
During Thursday's session, 97 companies made new 52-week lows. Noteworthy Points From Today's 52-Week ...
01 Nov, 2022
On Tuesday, 85 stocks hit new 52-week lows. Points of Interest From Today's 52-Week Lows: The largest company by ...
19 Oct, 2022
Figure: 1 Compound F3 and enhanced activity derivative F3-8-60 directly bind to K-RAS Figure: 2 F3 class compounds block RAS signaling. Figure: 3 F3-8-60 Suppresses MPNST cell line tumor growth Figure: 4 F3-8-60 suppresses MPNST pdx growth Figure: 5 NMR studies demonstrate F3-8-60 binds K-RaS12D and promotes changes in effector domain structure. Figure: 6 F3-8-60 is active in vivo against pancreatic cancer models. Figure: 7 F3-8-60 enhances the effect of Immune Checkpoint inhibitors. Fourth RAS
18 Oct, 2022
CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Amy Broidrick, President and Chief Strategy Officer, and Tariq Arshad, MD, Chief Medical Officer, will present a corporate overview at the LD Micro Main Event XV. The conference is being held on Oct
14 Oct, 2022
Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares rose 80.1% to $0.4161 in pre-market trading after declining around ...
06 Oct, 2022
CARLSBAD, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that two abstracts detailing the Company’s RAS-Targeted platform have been accepted to be presented as posters at the National Cancer Institute-sponsored Fourth RAS Initiative Symposium to be held Octobe
23 Sep, 2022
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company ...
14 Sep, 2022
Qualigen Therapeutics, Inc. Receptors for cardiac and neurological function Qualigen Therapeutics, Inc. Vehicle BIW QN-302 Qualigen Therapeutics, Inc. Normalised heart rate Posters include data regarding 1) mode of action, and 2) preclinical toxicology CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while
26 Aug, 2022
During Friday's session, 132 stocks hit new 52-week lows. Noteworthy Highlights From Today's 52-Week ...
25 Aug, 2022
10:45
Yahoo! Finance
By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update IND-Enabling Studies Underway for QN-302 In June 2022, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced it has commenced Investigational New Drug (IND)-enabling studies for its lead therapeutic program, QN-302, which include initial safety and pharmacology studies. Exploratory toxicology studies are expected to
18 Aug, 2022
CARLSBAD, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has formed a Scientific Advisory Board (SAB) in support of the development of its lead therapeutic candidate QN-302 for the potential treatment of pancreatic cancer and other G4-prevalent solid tumors
16 Aug, 2022
Q2 2022 FastPack ® Sales increased approximately 28%, and gross profit on product sales was up 64% year-over-year from Q2 2021 Milestone achievements in QN-302 and QN-247 oncology therapeutic programs and acquisition of majority stake in NanoSynex strengthen Company’s diversified product portfolio CARLSBAD, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with
03 Aug, 2022
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on ...
01 Aug, 2022
CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has completed its in vivo efficacy analysis of QN-247 in solid tumors. Data demonstrates robust efficacy and no safety signals in a triple negative breast cancer (TNBC) model. Committed to an in vivo
06 Jul, 2022
Gainers AcelRx Pharmaceuticals (NASDAQ:ACRX) stock increased by 38.9% to $0.36 during Wednesday's after-market session. AcelRx ...
CARLSBAD, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces its partnership with China-based Hande Sciences (“Hande”) to conduct manufacturing scale-up activities to support the Company’s IND-enabling good laboratory practice (GLP) studies for its lead therapeuti
23 Jun, 2022
U.S. stocks traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders ...
16 Jun, 2022
Gainers Acorda Therapeutics (NASDAQ:ACOR) shares increased by 49.9% to $0.6 during Thursday's pre-market session. ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news for Thursday morning. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now Stock Prodigy Who Found NIO at $2… Says Buy THIS Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 in savings or $5 million. Do this now.
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday ...
07 Jun, 2022
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
18 May, 2022
Gainers Kiromic BioPharma (NASDAQ:KRBP) shares moved upwards by 17.3% to $0.4 during Wednesday's pre-market session. ...
10 May, 2022
Gainers Biohaven Pharma Hldgs (NYSE:BHVN) stock moved upwards by 72.6% to $143.49 during Tuesday's pre-market ...
03 May, 2022
Qualigen Therapeutics Inc(NASDAQ: QLGN) hasagreed to acquire a majority stakeinNanoSynex Ltd, an ...
Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares rose 38% to $3.69 in pre-market trading. Sonoma Pharmaceuticals and ...
13 Apr, 2022
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. 10 Stocks Are Issuing Sell Signals Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
12 Apr, 2022
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket. The post Biotech Stocks News: What’s Going on With LIXT, PTE, QLGN and ATNM Stocks Today? appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. 10 Stocks Are Issuing Sell Signals Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
Gainers Zosano Pharma (NASDAQ:ZSAN) stock moved upwards by 2670.4% to $3.33 during Tuesday's regular session. Trading volume for this ...
Qualigen Therapeutics Inc(NASDAQ: QLGN) shares are surging after highlighting posters at the American Association of Cancer ...
25 Feb, 2022
09:47
FinancialContent
Gainers Cyren Ltd. (NASDAQ: CYRN) shares surged 118.9% to settle at $4.75 on Thursday. Cyren recently announced a $12 million ...
24 Feb, 2022
Gainers Indonesia Energy Corporation Limited (NYSE: INDO) shares climbed 66.7% to $12.55 following a 16% surge on ...
Gainers Imperial Petroleum Inc.(NASDAQ: IMPP) rose 45.1% to $1.64 in pre-market trading after gaining around 41% on ...
14 Feb, 2022
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 ...
30 Dec, 2021
09:17
FinancialContent
Gainers Puxin Limited (NYSE: NEW) shares surged 80% to close at $0.54 on Wednesday after reporting results for the second ...
29 Dec, 2021
Gainers Biofrontera (NASDAQ:BFRI) shares increased by 15.6% to $9.37 during Wednesday's regular session. The current ...
28 Dec, 2021
Gainers Flotek Industries, Inc. (NYSE: FTK) rose 48.6% to $0.8322 in pre-market trading after the company said it had received an ...
27 Dec, 2021
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE: ...
23 Dec, 2021
Gainers Pasithea Therapeutics (NASDAQ:KTTA) stock increased by 33.33% to $1.96 during Thursday's regular session. As ...
29 Nov, 2021
Gainers Krystal Biotech (NASDAQ:KRYS) shares moved upwards by 118.21% to $86.87 during Monday's regular session. ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips I hope you got your rest out over the holiday weekend because we're starting off Monday with the biggest pre-market stock movers! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...
26 Nov, 2021
10:41
FinancialContent
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced ...
19 May, 2021

Related Articles